Goodman A, Zukerberg L R, Nikrui N, Scully R E
Department of Gynecology, Massachusetts General Hospital, Boston.
Cancer. 1991 Oct 1;68(7):1628-32. doi: 10.1002/1097-0142(19911001)68:7<1628::aid-cncr2820680727>3.0.co;2-r.
Vaginal adenosis and clear cell adenocarcinoma of the vagina occurred in a 44-year-old woman after treatment for condylomata acuminata. She had no known exposure to diethylstilbestrol (DES) in utero. Biopsy-proven vaginal adenosis appeared 8 months after intravaginal 5-fluorouracil application for recurrent urogenital condylomata acuminata. Forty months later, biopsies showed residual adenosis with foci of clear cell adenocarcinoma. Although clear cell adenocarcinoma is associated with vaginal adenosis and cervical ectropion in DES-exposed women, its occurrence in adenosis after 5-fluorouracil therapy has not been reported to the authors' knowledge. In this report, this rare but serious complication of treatment of condylomata acuminata is highlighted, and the literature regarding the development of non-DES-associated vaginal adenosis is discussed.
一名44岁女性在接受尖锐湿疣治疗后出现阴道腺病和阴道透明细胞腺癌。她在子宫内未接触过已知的己烯雌酚（DES）。经活检证实的阴道腺病在阴道内应用5-氟尿嘧啶治疗复发性泌尿生殖系统尖锐湿疣8个月后出现。40个月后，活检显示残留腺病伴有透明细胞腺癌灶。虽然透明细胞腺癌在接触DES的女性中与阴道腺病和宫颈外翻有关，但据作者所知，5-氟尿嘧啶治疗后腺病中出现透明细胞腺癌尚未见报道。在本报告中，强调了这种尖锐湿疣治疗中罕见但严重的并发症，并讨论了关于非DES相关阴道腺病发生的文献。
